Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXA1665 in liver cirrhosis with prior overt hepatic encephalopathy
NCT04816916Phase 2Terminated
- Sponsor
- Axcella
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 2 trial of AXA1665 in hepatic encephalopathy (HE), sponsored by Axcella. Started Jun 2021; status: terminated.
02
Drugs
AXA1665
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT04816916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816916.